phrykt

Haemonetics Corp (HAE): who owns it and who trades it

As of Nov 16, 2026, HAE insiders reported 1 open-market sale worth $101K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Farris Maryanne Maunsell (Vice president), with $101K. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Haemonetics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, HAE insiders reported $0 of open-market purchases and $101K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$101K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$101K$101KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Farris Maryanne MaunsellVice presidentSale836$120.99$101KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Farris Maryanne MaunsellVP, Chief Accounting Officer–$101KNov 11, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HAE short interest

Moderate short interest. 7.9% of HAE shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went up 39%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.60M HAE shares were sold short, 7.9% of the shares outstanding, up 5.0% from the report before. At the average daily volume of 574,460 shares, buying them all back would take about 6.3 trading days (days to cover).

Shares short, % of all shares

7.90%May 15Oct 308.24%

Days to cover

6.3May 15Oct 306.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.60M7.90%+5%574,4606.3
Oct 15, 20263.43M7.53%+13%881,2913.9
Sep 30, 20263.04M6.68%-11%569,3155.3
Sep 15, 20263.42M7.53%+20%602,0885.7
Aug 31, 20262.86M6.29%+4%841,7723.4
Aug 14, 20262.76M6.07%-5%888,7973.1
Jul 31, 20262.92M6.42%+8%638,6544.6
Jul 15, 20262.70M5.94%-7%640,7814.2
Jun 30, 20262.91M6.41%-3%931,3153.1
Jun 15, 20263.01M6.63%+2%1.12M2.7
May 29, 20262.96M6.51%+14%953,9233.1
May 15, 20262.58M5.68%+30%1.06M2.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Haemonetics company events

Haemonetics filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 8, 2026AnnouncementShared information with investors. Filing
  3. Aug 18, 2026AnnouncementShared information with investors. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Jul 28, 2026LeadershipThe Board of Directors of Haemonetics Corporation elected Martin Madaus as a director of the Company, effective immediately. Filing
  6. Jun 5, 2026AnnouncementShared information with investors. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. May 1, 2026LeadershipCharles J. Dockendorff informed Haemonetics Corporation that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders. Filing
  9. Mar 3, 2026AnnouncementShared information with investors. Filing
  10. Feb 12, 2026AnnouncementShared information with investors. Filing
  11. Feb 5, 2026ResultsReleased financial results. Filing
  12. Jan 9, 2026AnnouncementHaemonetics Corporation announced its acquisition of Vivasure Medical Limited, a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Haemonetics financials

Famous investors that hold HAE

6 of the 50 well-known investors we track reported holding HAE in their latest 13F filing. The largest position is Ken Griffin's, worth $175M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.66M$175M0.1%+10%
Steve Cohen · Point72 Asset ManagementQ3 2026893,201$94.1M0.2%+718%
Israel Englander · Millennium ManagementQ3 2026636,895$67.1M0.1%+12%
Jim Simons · Renaissance TechnologiesQ3 2026144,300$15.2M0.0%+11%
Paul Tudor Jones · Tudor Investment CorpQ3 2026104,753$11M0.1%New
Ray Dalio · Bridgewater AssociatesQ3 202673,411$7.7M0.0%+23%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Haemonetics Corp (HAE) stock

Are HAE insiders buying or selling?

In the last 12 months, HAE insiders reported no open-market purchases and 1 sale worth $101K. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in HAE?

As of Oct 30, 2026, 3.60M HAE shares were sold short, 7.9% of the shares outstanding, up 5.0% from the report before. At the average daily volume of 574,460 shares, buying them all back would take about 6.3 trading days (days to cover). See the history.

Which famous investors hold HAE?

6 of the 50 well-known investors we track reported HAE in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $175M. See all holders.

Executive pay

Haemonetics's chief executive was paid a total of $12M for the year ended Mar 28, 2026, up 12% from $10.7M the year before. In the last 12 months, Haemonetics's executives and directors bought no stock on the open market and sold $101K.

Chief executive, total pay$12MYear ended Mar 28, 2026. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$8.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.